Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate

There is a strong association between weight gain and metabolic events in patients with schizophrenia receiving many of the second-generation antipsychotic agents. We explored the relationship between body mass index (BMI) and metabolic events in patients with schizophrenia receiving long-acting inj...

Full description

Saved in:
Bibliographic Details
Published in:BMC psychiatry 2014-02, Vol.14 (1), p.52-52, Article 52
Main Authors: Sliwa, Jennifer Kern, Fu, Dong-Jing, Bossie, Cynthia A, Turkoz, Ibrahim, Alphs, Larry
Format: Article
Language:English
Subjects:
Adult
Analysis
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - adverse effects
Antipsychotic Agents - therapeutic use
Blood Glucose
Blood levels
Body Mass Index
Body Weight - drug effects
Care and treatment
Complications and side effects
Double-Blind Method
Ethics
Female
Glucose
Humans
Insulin resistance
Isoxazoles - administration & dosage
Isoxazoles - adverse effects
Isoxazoles - therapeutic use
Lipids - blood
Male
Mental disorders
Middle Aged
Mortality
Obesity - blood
Obesity - chemically induced
Paliperidone Palmitate
Palmitates - administration & dosage
Palmitates - adverse effects
Palmitates - therapeutic use
Patient compliance
Psychiatry
Psychotropic drugs
Review boards
Schizophrenia
Schizophrenia - blood
Schizophrenia - drug therapy
Studies
Weight Gain - drug effects
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is a strong association between weight gain and metabolic events in patients with schizophrenia receiving many of the second-generation antipsychotic agents. We explored the relationship between body mass index (BMI) and metabolic events in patients with schizophrenia receiving long-acting injectable paliperidone palmitate (PP) in a long-term trial. We conducted a post hoc analysis of data from a PP study that included a 33-week open-label transition (TR) and maintenance phase; a variable duration, randomized, double-blind (DB), placebo-controlled phase and a 52-week open-label extension (OLE) phase. Overall, 644 patients received PP continuously from study entry through discontinuation or study completion and were grouped by baseline BMI (kg/m2): underweight (BMI
ISSN:1471-244X
1471-244X
DOI:10.1186/1471-244X-14-52